All generic medications must undergo certain tests to compare them to brand-name medications. The U.S. Food and Drug Administration (FDA) then looks at these tests to decide if the generics are equivalent to the brand-name medications and assigns a rating to each one.
An "AB" rating means that the FDA has determined that a generic medication is equivalent to a brand-name medication. All of the generic versions of CellCept currently available have an "AB" rating, meaning they should be equivalent to CellCept.
However, generic medications are allowed to have different inactive ingredients than the brand-name medication. This might include fillers, dyes, or other ingredients that could cause problems for people with allergies.
At this time, the other mycophenolate medications are protected by patents that prevent any generic versions from being manufactured in the United States. The patents need to expire before a generic version can become available.
The patent for Myfortic currently expires in April 2017, the patent for CellCept oral liquid suspension expires in November 2014, and the patent for CellCept intravenous injection already expired in September 2013, although it is not yet available in generic form, for unclear reasons.
Other circumstances could come up to extend or shorten the exclusivity periods. This could include such things as lawsuits or other patents for specific mycophenolate uses. Once the drug goes off-patent, there may be several companies that manufacture a generic mycophenolate drug.
No -- mycophenolate is the active ingredient in CellCept and Myfortic, but it is not a generic version of the medications. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.